Iceland· IS-890099

Lopid

A gemfibrozil product containing gemfibrozilum inn, registered in Iceland by Pfizer ApS. The same ATC class is registered in 12 of our 19 countries.

ATC C10AB04

Checked against Icelandic Medicines Agency (Iceland) on

Informational only — not a medical device.

SOURCE REGISTER · ISIcelandic Medicines Agency (Iceland)normalisedLopidATCC10AB04REGISTER NO.IS-890099PACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Gemfibrozil is registered in 12 of 19 countries.

Countries holding a registration under ATC C10AB04 (gemfibrozil), each read from that country’s own register.

  • This record: Iceland, from Icelandic Medicines Agency (Iceland)
  • 6 of them publish a price we can compare per daily dose

Gemfibrozil · ATC C10AB04

12 / 19 countries

  • Canada
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of gemfibrozil costs, country by country.

Normalised to the WHO defined daily dose (1.2 g), so markets compare like for like.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Gemfibrozil · price per daily dose (1.2 g)

USD · FX 28 Sept 2026

  • FR France$0.50
  • IT Italy$0.42
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Icelandic Medicines Agency (Iceland)
Active substance
Gemfibrozilum INN
Manufacturer
Pfizer ApS
Country
Iceland (IS)
ATC code
C10AB04
ATC class
Gemfibrozil
Defined daily dose
1.2 g, O
Reimbursed
Not published by this register
Source register
Icelandic Medicines Agency (Iceland)
Last checked
September 29, 2026

Packs & prices · 1

1 priced
  • ean
    469346
    98 stk x1 þpakki
    ISK 5513

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

165 interactions on record for gemfibrozil.

Graded by severity as the source publishes them — 19 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Gemfibrozil · interactions on record

165 records

  • 19 severe
  • 57 moderate
  • 2 minor
  • 85 info

Most severe, free to view

  • LoperamideA07DA03severe
  • EluxadolineA07DA06severe
  • PioglitazoneA10BG03severe
  • RepaglinideA10BX02severe

2 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Gemfibrozil in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All gemfibrozil products

Authorised across Europe · EMA

The same active substance is authorised in 11 EEA countries. Names it is sold under:

  • Austria · Gevilon
  • Cyprus · Ipolipid, Lipofor
  • Denmark · Lopid
  • Spain · Gemfibrozilo Stada, Gemfibrozilo Tarbis
  • France · Lipur
  • United Kingdom (Northern Ireland) · Gemfibrozil Tillomed Laboratories, Lopid
  • Greece · Fibrolip, Gemlipid
  • Ireland · Lopid
  • Italy · Gemfibrozil Doc Generici, Gemfibrozil Eg
  • Netherlands · Gemfibrozil Aurobindo, Lopid
  • Portugal · Gemfibrozil Generis, Lopid

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/27c7a95e-400b-4ab6-9bd7-dc83347abf71
GET /v1/drugs/27c7a95e-400b-4ab6-9bd7-dc83347abf71?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmuhúðuð tafla",
  "source": "lyfjastofnun",
  "atc_raw": "C10AB04",
  "marketed": true,
  "strength": "600 mg",
  "ma_number": "890099",
  "substance": "Gemfibrozilum INN",
  "other_info": null,
  "legal_status": "(R) Lyfseðilsskylt",
  "ma_issued_serial": "33420"
}

See everything about gemfibrozil.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.